Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


Vitae Pharmaceuticals, Inc.

Unaudited Condensed Statements of Operations

 
  For The Six Months Ended
June 30,
 
 
  2014   2013  

Collaborative revenues

  $ 2,328,947   $ 1,962,298  

Operating expenses:

             

Research and development

    9,425,258     7,584,627  

General and administrative

    2,628,291     2,679,783  
           

Total operating expenses

    12,053,549     10,264,410  
           

Loss from operations

    (9,724,602 )   (8,302,112 )

Other (expenses) income:

             

Other income

    217,774     303,891  

Interest income

    28,815     43,106  

Interest expense

    (541,037 )   (768,215 )
           

Total other (expenses) income

    (294,448 )   (421,218 )
           

Net loss

  $ (10,019,050 ) $ (8,723,330 )
           
           

Per share information:

             

Net loss per common share:

             

Basic

  $ (0.73 ) $ (0.69 )

Diluted

  $ (0.73 ) $ (0.69 )

Weighted-average number of common shares:

             

Basic

    13,770,634     12,697,213  

Diluted

    13,770,634     12,697,213  

Unaudited pro forma net loss per common share:

             

Basic

  $ (0.04 )      
             
             

Diluted

  $ (0.04 )      
             
             

Unaudited pro forma weighted-average number of common shares:

             

Basic

    232,080,375        
             
             

Diluted

    232,080,375        
             
             

   

The accompanying notes are an integral part of these unaudited condensed financial statements.

F-34